VACH
NASDAQVoyager Acquisition Corp
IPO2024
News25/Ratings0
News · 26 weeks25-71%
2025-12-282026-06-21
Mix1190d
- Other6(55%)
- SEC Filings3(27%)
- Offering2(18%)
Latest news
25 items- PRVERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs)Strengthened financial position with $27.5 million principal amount senior secured note financing and $50 million share purchase agreement to advance VERAXA's pipeline of oncology drug candidates utilizing its novel BiTAC platformVERAXA recently presented promising data supporting the underlying principle of its novel BiTAC platform technology at the American Association for Cancer Research (AACR) 2026 Annual MeetingVERAXA's common stock
- SECSEC Form 25-NSE filed by Voyager Acquisition Corp25-NSE - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECVoyager Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- PRVERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase AgreementTransactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies Comprised of Novel Bispecific T-cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs)Support Closing of Business Combination with Voyager Acquisition Corp. ZURICH, SWITZERLAND – May 28, 2026 – VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies, today announced that it has strengthened its financial position to support the closing of its business combination with Voyager Acquisition Corp. ("Voyager") and support advancement of its pipeline of BiTAC-TCE and BiTAC-ADC programs toward clinical development and through initial value inflection points. In con
- SECSEC Form 10-Q filed by Voyager Acquisition Corp10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECSEC Form NT 10-Q filed by Voyager Acquisition CorpNT 10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Voyager Acquisition Corp10-K/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECVoyager Acquisition Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- PRVoyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AGBROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") held the general meeting on March 12, 2026 and approved the previously announced business combination (the "Business Combination") with VERAXA Biotech AG ("VERAXA"). After the closing of the Business Combination, it is expected that the combined company will trade on Nasdaq under the new symbol ("VRXA"). As previously announced, holders of 25,217,315 of the Company's Class A ordinary shares ("Class A shares") exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- PRVoyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AGBROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") today announced that holders of 25,217,315 of the Company's Class A ordinary shares ("Class A shares") exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of approximately 99.67% of the total Class A shares outstanding in connection with the completion of the Company's business combination (the "Business Combination") pursuant to the business combination agreement between the Company, VERAXA Biotech AG ("VERAXA") and the other parties thereto (the "Business Combi
- SECSEC Form 10-K filed by Voyager Acquisition Corp10-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- PRVERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.ZURICH, SWITZERLAND – March 2, 2026 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting ("EGM") on February 27, 2026. Both resolutions are prerequisites for the closing of the proposed business combination (the "Business Combination") among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager"), "Voyager"), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon
- SECVoyager Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECSEC Form SCHEDULE 13G filed by Voyager Acquisition CorpSCHEDULE 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECVoyager Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
VACH FAQ
3 questionsWhere does VACH stock trade?
Voyager Acquisition Corp (VACH) is listed on NASDAQ.When did Voyager Acquisition Corp go public?
Voyager Acquisition Corp (VACH) completed its IPO in 2024.How can I track VACH on Quantisnow?
Quantisnow aggregates Voyager Acquisition Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VACH to receive live email and push alerts on every new disclosure.